3rd Quarter - Report
HOSPIRA, INC. for HOSPIRA INC
Firm
Client
Income
—
Expenses
$280,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Issues relating to drug shortages; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIANA REED | — |
| WENDY SUSSMAN | — |
Health Issues HCR
Implementation of the Biologics Price Competition and Innovation Act (BPCIA) relating to biosimilar naming and reimbursement; issues related to drug approvals at the FDA including biosimilars.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIANA REED | — |
| WENDY SUSSMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.